Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Yeast Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Beta-glucan and Immune Response to Influenza Vaccine

NCT05074303
View directory record Official record
Conditions
Healthy Aging
Interventions
Influenza Vaccine, Beta-glucan, Placebo
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 100 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

Point of Care Diagnosis of Vaginal Infections

NCT06438575
View directory record Official record
Conditions
Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
Interventions
Xpert® Xpress MVP test, Usual Care
Diagnostic Test
Lead sponsor
Sharon L Hillier
Other
Eligibility
14 Years and older · Female only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 2:18 AM EDT
Recruiting Not applicable Interventional

Clinical Protocol CERN Feasibility Study

NCT06933420
View directory record Official record
Conditions
Bacterial Vaginosis, Fungal Vaginal Infections
Interventions
Cern Device
Device
Lead sponsor
Cern Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Irvine, California • Orange, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 22, 2026, 2:18 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparative Performance of a Vaginal Yeast Test

NCT05079711
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
Device
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Fort Bragg, North Carolina • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

NCT01891331
View directory record Official record
Conditions
Candidiasis, Vulvovaginal
Interventions
VT-1161, Fluconazole
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 22, 2026, 2:18 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448
View directory record Official record
Conditions
Autosomal-dominant Hyper-IgE Syndrome
Interventions
NDV-3A
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

NCT00000972
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
MTP-PE/MF59, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1992
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 22, 2026, 2:18 AM EDT
Not listed Not applicable Interventional

Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis

NCT00417365
View directory record Official record
Conditions
Vaginal Odor
Interventions
WaterWorks Douching Device
Device
Lead sponsor
Abbott Research Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Aventura, Florida • Plantation, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Jul 22, 2026, 2:18 AM EDT
Recruiting Not applicable Interventional

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

NCT06983041
View directory record Official record
Conditions
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions
vaginal cooling device
Device
Lead sponsor
Coologics, Inc
Industry
Eligibility
22 Years to 49 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 22, 2026, 2:18 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women

NCT01915251
View directory record Official record
Conditions
Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

NCT04029116
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 22, 2026, 2:18 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:18 AM EDT
Not yet recruiting Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jul 22, 2026, 2:18 AM EDT
Not yet recruiting No phase listed Observational

Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples

NCT06531031
View directory record Official record
Conditions
Bloodstream Infection, Sepsis, Septic Shock
Interventions
InfectID-BSI (Bloodstream Infection) qPCR Assay
Diagnostic Test
Lead sponsor
Microbio Co Ltd
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT02267382
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
VT-1161, Placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

NCT03930745
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Placebo, TOL-463
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional

Candin for the Treatment of Common Warts

NCT05889845
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Candin, Intradermal Solution, Placebo
Drug
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 22, 2026, 2:18 AM EDT
Completed No phase listed Observational

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

NCT00721487
View directory record Official record
Conditions
Fungal Infection by Site
Interventions
Fluconazole
Drug
Lead sponsor
CPL Associates
Other
Eligibility
4 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Jul 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

NCT00634049
View directory record Official record
Conditions
Aspergillosis, Invasive Fungal Infections
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 22, 2026, 2:18 AM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Jul 22, 2026, 2:18 AM EDT